Aubrey, Brandon J. http://orcid.org/0000-0002-1372-3107
Brennan, Margs S.
Diepstraten, Sarah T. http://orcid.org/0000-0002-1946-5161
Wang, Zilu
Chang, Catherine
Herold, Marco J. http://orcid.org/0000-0001-7539-7581
Strasser, Andreas http://orcid.org/0000-0002-5020-4891
Kelly, Gemma L. http://orcid.org/0000-0002-6533-1201
Funding for this research was provided by:
Leukaemia Foundation National Research Program Clinical PhD Scholarship
Cancer Council Victoria (1086157, 1147328)
Leukaemia Foundation PhD Scholarship
Department of Health | National Health and Medical Research Council (1145728, 1143105, 1186575, 1159658, 1156095, 1016701, 1020363, 1086291, 2002618, 2001201)
Leukemia and Lymphoma Society (7001-13, 7001-13)
Anthony Redstone Estate
Leukemia and Lymphoma Society
Victorian Cancer Agency (17028)
Leukemia Foundation Australia, Dyson Bequest, Craig Perkins Cancer Fund
Article History
Received: 10 June 2021
Revised: 18 January 2022
Accepted: 18 January 2022
First Online: 28 January 2022
Competing interests
: AS, GLK, STD, ZW, CC and MJH are currently, and BJA and MSB have previously been, employees of the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, which receives Royalties and Milestone payments related to the BCL-2 inhibitor, Venetoclax/ABT-199. AS, GLK and MH have received research funding from Servier.
: All experiments with mice followed the guidelines of the Melbourne Directorate Animal Ethics Committee, according to The Walter and Eliza Hall Institute of Medical Research Ethics Committee.